More importantly, Interleukin-4-induced-1 (IL4I1) as a metabolic immune checkpoint, activates the Aryl hydrocarbon receptor (AHR), circumvents Immune Checkpoint Blockade (ICB) and further elicits major effects in immunosuppression shaping tumor microenvironment [52]. The gene discussed is AHR; the disease is neoplasm.